<DOC>
	<DOCNO>NCT00742131</DOCNO>
	<brief_summary>This clinical study conduct two site determine optimum dose , safety , tolerability GSK1363089 treatment adult solid tumor . This study longer recruit subject .</brief_summary>
	<brief_title>A Dose Escalation Study Safety Pharmacokinetics GSK1363089 ( Formerly XL880 ) Administered Orally Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically confirm solid tumor metastatic unresectable know effective treatment measure , ECOG performance status &lt; /= 2 . Adequate bone marrow reserve , hepatic , renal , cardiovascular function , Negative pregnancy test . Chemotherapy within 46 week start treatment , Radiotherapy within 4 week start treatment , Known brain metastasis , Uncontrolled medical disorder infection cardiovascular disease , HIV positive , Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MET inhibitor</keyword>
	<keyword>c-Met</keyword>
	<keyword>XL880</keyword>
	<keyword>GSK1363089</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>